Combination therapy incorporating Bcl‐2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|100|2|215-217

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.100, Iss.2, 2018-02, pp. : 215-217

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 401-407

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Plasma Cell Leukemia Patient Showing Bialleic 14q Translocations: t(2;14) and t(11;14)

By  

Acta Haematologica, Vol. 101, Iss. 4, 1999-07 ,pp. : 197-201

Karger

Access to resources Recommend Favorite

Novel Agents for the Treatment of Primary Plasma-Cell Leukemia: Lights and Shadows

By  

Acta Haematologica, Vol. 135, Iss. 2, 2016-0 ,pp. : 110-112

Karger

Access to resources Recommend Favorite

Survival following salvage therapy for primary refractory peripheral T‐cell lymphomas (PTCL)

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 394-400

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful Treatment of Adult T‐cell Leukemia/Lymphoma with MACOP‐B, M‐FEPA and VEPP‐B Combination Chemotherapy

By  

THE JOURNAL OF DERMATOLOGY, Vol. 20, Iss. 10, 1993-10 ,pp. : 623-629

John Wiley & Sons Inc

Access to resources Recommend Favorite